Trump announces 'TrumpRx' website for pharmaceutical drugs after Pfizer deal
While President Donald Trump announced on Tuesday that Pfizer, one of the leading pharmaceutical companies, had agreed to lower its prices for prescription drugs offered through Medicaid, he also revealed his administration's goal of launching a "TrumpRx" website.
The president said the site would be a place where Americans can buy prescription medications at a discounted rate directly, not through insurance. He said the move would help improve healthcare access for low-income Americans.
"This is a critical step forward [in] our work to improve healthcare in hard-working, low-income Americans -- especially low-income Americans, will be helped so greatly," Trump said.
A senior Trump administration official told ABC News after the announcement that the White House "hopes" to make the TrumpRx website available in early 2026. It would be a convening site where Americans can go and "know" they are getting the best price, according to the official.
"The place where they can go direct-to-consumer and access the lowest prices available," the official said.
Current direct-to-consumer pharmaceutical websites have a price below the full cash price but are often higher than the out-of-pocket costs for people with insurance.
For instance, the cash price for the popular weight loss drug Wegovy is over $1000 a month, the direct-to-consumer price is $499, but for people with insurance that covers the GLP-1 medication they pay $25 or less a month.
The announcement of TrumpRX comes as PhRMA, the group that represents many U.S. pharmaceutical companies, announced a similar website on Monday for direct-to-consumer sales that is set to go live in January 2026.
Earlier on Tuesday, Chris Klomp, the director of Medicare at the Centers for Medicare and Medicaid, said that Pfizer had agreed not to charge the U.S. more than other countries for any drug through Medicare, Medicaid or cash payments — and that other manufacturers will follow suit.
U.S. pharmaceutical companies have already pledged $500 billion in new U.S. manufacturing investment, according to PhRMA.
Trump was joined by the CEO of Pfizer, Albert Bourla, Health and Human Services Secretary Robert F. Kennedy Jr., Administrator for the Centers for Medicare & Medicaid Services, Mehmet Oz, and FDA Commissioner Martin Makary for the announcement.
"I'm thrilled to announce that one of the world's largest pharmaceutical manufacturers and one of the best anywhere in the world, Pfizer, has agreed to offer countless prescription medications at major discounts in the United States, a result of the most favored nation drug pricing order that we established earlier this year," Trump said.
It's not clear what the impact will be for people with private insurance.
It comes after Trump in May signed an executive order to pressure companies to only charge U.S. patients the same rate as they charge in other countries, an effort called "most favored nation" pricing. That kicked off a monthslong campaign to pressure pharmaceutical companies to drop their prices voluntarily, without regulation. Pfizer is one of the first victories scored by the administration.
Trump said the administration has repeatedly threatened tariffs if companies didn't comply with "most favored nation" pricing.
"Nobody wanted to play that game," Trump said.
Pfizer will avoid tariffs for another three years under the current deal, which also includes a $70 billion commitment from the company to increase manufacturing in the U.S.
The pharmaceutical giant currently has nine manufacturing plants in 11 states.
